In a report released today, Neil Chatterji from B.Riley Financial maintained a Buy rating on ClearPoint Neuro (CLPT – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $9.10.
According to TipRanks, Chatterji is a 2-star analyst with an average return of -0.7% and a 41.03% success rate. Chatterji covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, PROCEPT BioRobotics, and Butterfly Network.
ClearPoint Neuro has an analyst consensus of Moderate Buy, with a price target consensus of $18.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $16.96 and a one-year low of $7.08. Currently, ClearPoint Neuro has an average volume of 71.12K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clearpoint Neuro, Inc. engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart. It conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform is comprises of ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Irvine, CA.
Read More on CLPT:
- ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles
- CLPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
- ClearPoint Neuro with teams with NE Scientific on software solution
- ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain Model
